Linked Life Data

16396699

Source:http://linkedlifedata.com/resource/pubmed/id/16396699

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2006-1-10
pubmed:abstractText
Selective inhibitors of cyclo-oxygenase-2 (COX-2) appear to be safer than conventional NSAIDs on the gastrointestinal (GI) tract. Amtolmetin guacyl (AMG), a NSAID that inhibits both COX-1 and COX-2, has an anti-inflammatory effect comparable to that of traditional NSAIDs, with a better GI safety profile. The primary end-point of this study was to evaluate the gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients affected with rheumatoid arthritis. The assessment of efficacy was the secondary end-point.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0392-856X
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
809-18
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis.
pubmed:affiliation
Department for Rheumatology, Physical Medicine and Rehabilitation, Medical Faculty University of Zagreb, Referral Centre for Inflammatory Rheumatic Disease, Zagreb, Croatia. zjajic@mef.hr
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Multicenter Study